BRIEF

on VETOQUINOL (EPA:VETO)

Vetoquinol Reports 9-Month Sales Decline, Despite Essential Product Growth

Stock price chart of VETOQUINOL (EPA:VETO) showing fluctuations.

Vetoquinol reported a 3.5% decline in sales at the end of September 2025, amounting to €384.2 million. At constant exchange rates, sales fell by 1.3%. The company experienced a €8.9 million negative currency impact across the Americas and Asia-Pacific, alongside a €7.7 million impact from simplifying complementary product ranges, particularly in Europe.

Despite the overall decline, sales of Essential products rose to €244.2 million, making up 64% of total sales, marking a 2.7% increase at constant exchange rates. This internal growth reflects ongoing adjustments from the transfer of certain product manufacturing to Vetoquinol's facilities.

Regional performance varied: European sales decreased, partly due to product line simplification, while the U.S. showed a 7.5% organic increase in Q3 2025, boosting its 9-month growth to 1.2%. Companion animal products generated €276 million, representing 72% of sales.

R. E.

Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all VETOQUINOL news